Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma

The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with ovarian carcinoma.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Ovarian Carcinoma Adnexal Diseases Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Neoplasms Neoplasms by Site Ovarian Diseases Ovarian Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

30 year–70 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

About this study

The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with ovarian carcinoma.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients diagnosed with FIGO stage II ovarian carcinoma;
cytoreductive surgery performed and 6 courses of platinum-based chemotherapy completed;
medical records maintain comprehensive data on treatment and follow-up;
no history of previous malignancies.

Exclusion criteria

neoadjuvant chemotherapy applied;
less than 6 courses of chemotherapy or more than 6 courses of chemotherapy completed;
medical records maintain incomplete data on treatment or follow-up;
history of previous malignancy.

Treatment and study plan

Radiofrequency ablation

Procedure

Radiofrequency ablation is performed percutaneously under CT/US guidance

Other names: RFA

Cytokine-Induced Killer Cells

Biological

The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.

Other names: CIK

Primary outcomes

Recurrence-free survival

Time frame: 1 year

Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up.

Secondary outcomes

Adverse events

Time frame: 4 weeks

Adverse events related to RFA and CIK treatments.

Sponsors and collaborators

Lead sponsor

The First People's Hospital of Changzhou

Other

Registry information

Important dates

Study start: 2015
Primary completion: 2038
Study completion: 2040
First posted: Jul 1, 2015
Registry last updated: Feb 23, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting